Quarterly ResultMay 13, 2026, 04:09 PM
OptimizeRx Q1 Net Loss Narrows to $0.495M; Authorizes $10M Buyback
AI Summary
OptimizeRx Corp reported a narrower net loss of $0.495 million for Q1 2026, a significant improvement from $2.199 million in Q1 2025, despite a 9.5% decrease in net revenue to $19.844 million. The company's Board authorized a share repurchase program of up to $10 million and extended the maturity date of its term loan to October 2029. Net cash used in operating activities was $0.467 million, a decrease from $3.864 million provided in the prior year.
Key Highlights
- Net loss narrowed to $0.495 million in Q1 2026, from $2.199 million in Q1 2025.
- Net revenue decreased by 9.5% to $19.844 million for Q1 2026.
- Loss per share improved to $(0.03) in Q1 2026, from $(0.12) in Q1 2025.
- Board authorized a share repurchase program of up to $10 million.
- Term loan maturity extended by two years to October 11, 2029.
- Repaid $2.691 million in long-term debt during Q1 2026.
- Net cash used in operating activities was $0.467 million in Q1 2026.
- Cash and cash equivalents stood at $20.169 million as of March 31, 2026.